Bora Pharmaceuticals Expands Sterile Fill/Finish Capacity in Baltimore

• Bora Pharmaceuticals will install a new isolator-based AST GENiSYS C fill/finish line at its Baltimore site to support increasing demand for drug product services.

• The line will support clinical and small-scale commercial supply, particularly for high-value and potent therapies.

Bora Pharmaceuticals has announced plans to expand its sterile fill/finish capacity at its Baltimore, Maryland facility, responding to sustained growth in demand for its drug product contract manufacturing services.

The company will install a new AST GENiSYS C automated line capable of handling vials, syringes, and cartridges. Scheduled for installation over the next year, the line will operate under full isolator conditions. It is intended to serve the needs of clinical and small-scale commercial production for high-value formulations, including potent compounds and treatments for rare and orphan diseases.

“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” said J.D. Mowery, President of Bora’s CDMO Division. “The addition of a precision small-scale isolator line adds to our overall capacity… and increases our flexibility and scalability.”

The Baltimore site spans 87,000 square feet and currently supports sterile injectable manufacturing. It includes four fill lines for vials and pre-filled syringes, along with services such as lyophilization, terminal sterilization, analytical testing, packaging, and serialization.

This expansion aims to strengthen Bora’s contract manufacturing offerings in the U.S. while enhancing its ability to accommodate both domestic and international clients.